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Abstract: This paper will propose a framework for evaluating translational research by 
identifying the way in which translational research occurs in practice (rather than the formal 
linear stages in which the results of such process are typically presented). Following previous 
work on methods to evaluation science-society interactions, our approach will focus on the 
processes of TR  and the ways in which public initiatives to support new ways of conducting 
research succeed or fail.  Our starting point is that TR is expressed through complex cycles where 
knowledge is moving back and forth through the bedside-to-bench continuum across various 
channels, giving rise to complex interactions between research performers and the user of the 
results of such research. The approach is rooted on empirical context of IDIBAPS, a university-
hospital joint institute in Barcelona, one of the European centre of excellence for TR, and a study 
on social networks and knowledge flows in the Spanish Biomedical Research Networking 
Centres (CIBERs). Further, we suggest that interactions between biomedical actors are less than 
optimal because the distances that separate these different groups make the interactions difficult. 
We end up by stating that learning processes and knowledge exchange interactions are facilitated 
and strengthened by five forms of proximity: cognitive, social, organisational, institutional and 
spatial. 
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1 Introduction	
The pathways between basic science and clinical practice and health outcomes are 
multifaceted and complex. The analysis of these pathways has become of interest to the 
biomedical research community and public health agencies. Researchers and funding 
agencies are concerned with the ways in which scientific breakthroughs and evidence-
based clinical findings are converted into practices with beneficial health impacts, 
including, but not limited to, therapies and medical guidelines. This interest is largely 
driven by the perception that many promising results from basic science in biomedicine 
have not systematically contributed to medical treatments and, ultimately, health care 
improvements.5 In response, a wide range of publicly-funded initiatives have been set up 
with the aim to address this problem. As the main aim of these initiatives is to facilitate 
the “translation” of scientific discoveries into beneficial applications and practices, many 
of these initiatives have been branded as “Translational Research” (TR).  
Translational Research has become a very popular term applied for instance, to large 
research programmes, research activities and, even, academic journals. Consequently, it 
has been the subject of fast growing interest, mainly from biomedical scholars and 
institutions (e.g. Marincola, 2003; Woolf, 2008; Zerhouni, 2007). The origins of the 
concept can be traced back to the 90s, when the U.S. National Cancer Institute (NCI) 
developed the Specialized Programs of Research Excellence (SPORE) (Lander & 
Atkinson-Grosjean, 2011). Starting in 1992, this program explicitly supported efforts to 
facilitate the “translation” of basic discoveries generated at academic centres into new 
interventions aimed to prevent and treat various types of cancer. Since then, many policy 
initiatives have given special attention to the transformation of basic knowledge into 
                                                 
5 Some analysts have gone as far as estimating that less than 10% of the most promising biomedical 
discoveries had resulted in any benefit to clinical practice two decades later (Contopoulos-Ioannidis, 
Ntzani, & Ioannidis, 2003; Ioannidis, 2004). 
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health benefits. In the US, the National Institute of Health (NIH) launched the Roadmap 
Initiative (Zerhouni, 2003), the Clinical and Translational Science Awards (Heller & de 
Melo-Martín, 2009), and, in December 2011, a $575 million National Center for 
Advancing Translational Sciences (NCATS6). TR initiatives have also been launched in 
the European Union (European Science Foundation, 2012) and its Member Countries. 
Some of them may be explicitly labelled as TR programmes, while others will have 
similar objectives and use the TR terminology as an element of the programme’s 
rationale. For example, in 2006 the Spanish Ministry of Health launched the Networked 
Centres of Biomedical Research (CIBER7) together with other research initiatives to 
facilitate the relationship between basic scientists and healthcare practitioners (Rey-
Rocha & Martín-Sempere, 2012). 
Often the more popular a policy concept, the more ambiguous it becomes. This has 
clearly been the case with Translational Research. A debate has emerged about the 
models of research that are to be considered “translational” and the nature and 
characteristics of a putative TR discipline (Littman et al., 2007). Consequently, the ways 
in which TR should be analysed, and more specifically the approaches to the evaluation 
of TR programmes are also the subject of debate. Given the substantial investments in 
TR programmes the definition of TR evaluation strategies and approaches has become an 
important element of the policy process.  
In a context of ambiguity about the type of activities to be considered as TR, evaluation 
approaches and practices can play an important role in determining what actions and 
outcomes are conceived in practice to be relevant and significant, and in so doing shaping 
                                                 
6 www.ncats.nih.gov  
7 CIBER is the Spanish acronym for “Centro de Investigación Biomédica en Red”. 
http://www.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-ejecucion/fd-centros-participados/fd-
consorcios2/cibers.shtml  
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the future nature of TR initiatives. This paper discusses the dominant approaches to TR 
evaluation and proposes an alternative evaluation framework, which would have 
implications both for TR evaluation processes and for the future shaping of TR 
programmes.  
We first provide an overview of the different ways in which TR is conceptualised. Many 
approaches see TR as activities that bridge gaps that occur in a continuum that stretches 
from basic research to the development and application of solutions and their health 
outcomes, while other views emphasize the research processes and how different groups 
interact and their role may be redefined under a TR initiative.  
Second, we discuss evaluation approaches associated with these different views of TR. A 
dominant approach is to focus on outputs generated at different points of the 
“translational research continuum” and when they are achieved. A focus on the “what” 
and “when” implies a TR evaluation approach that attempts to identify results and how 
these differ from what would have been achieved in the absence of the initiatives under 
assessment. It needs to be emphasized that this focus on outputs may be derived from an 
explicit view of TR that sees it as addressing “translational gaps” along a “translational 
research continuum”, or may emerge without an explicit “theory” of the processes and 
objectives of TR. Research is measured against success criteria revolving around the 
generation of outputs that are no different from those that may have been generated in a 
traditional research context, and this may be occurring in the absence of an explicit 
programme theory. Note that, in this case, the TR objectives may be defined by the 
evaluation strategy chosen. 
Our alternative is to focus, instead, on the “how”, on the processes of collaboration and 
exchange that can be attributed to TR initiatives. To this end we develop an alternative 
TR evaluation framework that focuses on understanding the processes of change and 
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their outputs across the divides that hinder the application of the capabilities and 
knowledge generated by basic biomedicine to health care. The extant literature attributes 
the low level of practical application of biomedical research to a variety of causes, 
including the divide between the interests and skills of basic scientists on the one hand 
and clinical scientists on the other, the growing difficulties of communication among 
both fields as biomedical research becomes more complex and specialized (Littman, Di 
Mario, Plebani, & Marincola, 2007), and the existence of institutional barriers (Lander & 
Atkinson-Grosjean, 2011). 
Following the conceptual framework proposed by Boschma (2005) we propose that TR 
initiatives can operate by generating “proximities” five different dimensions: cognitive, 
social, organisational, institutional and geographical. We define these dimensions and 
then illustrate how different TR initiatives can focus on a subset of dimensions and have 
effects across all of them. 
We conclude by exploring the implications of using our alternative approach to 
evaluation. TR addresses a problem that has organisational, social and cognitive roots: 
different communities, with different practices and values are involved in a process that 
is complex and difficult. Research organisations are generally described in terms of the 
outputs they produce: mainly publications, sometimes also patents and, in the case of 
medical research, clinical guidelines and practices. However, in order to understand what 
is different about TR programmes, one needs to investigate how research objectives and 
projects are designed, how research is conducted, and how the application of research 
results is conceived and carried out. In other words, we need to understand in detail, the 
variety of processes involved in TR initiatives. Focusing on outputs does not tell us 
anything about the reasons why such this output has or has not been generated according 
to the initial, implicit or explicit, expectations of stakeholders. Further, existing practices 
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may easily be relabelled as “transitional” if TR policies and their evaluation are just 
concerned about the generation of specific outputs and their identification. If TR 
initiatives are to become transformative, they need to implement changes in the way 
research and the development of clinical practices and therapies are carried out. This 
calls for an evaluation approach that focuses on these processes. 
2 Translational	Research:	a	variety	of	approaches	
TR reflects the perceived need to increase the chances that scientific discoveries will lead 
to benefits for patients, and emerged at a time when other initiatives flourished with the 
aim of facilitating the “valorisation” or uptake of research by socio-economic actors 
(Bozeman and Boardman, 2004). TR has become part of the policy discourse justifying 
many current research funding programmes. The inclusion of the TR discourse in the 
policy agenda has been accompanied by an intense academic discussion among 
biomedical scholars. What are the measures that need to be taken to speed up the process 
of application of biomedical research advances to clinical practice? How should we then 
characterise TR and evaluate TR initiatives? The development of a conceptual 
framework to describe the TR process and evaluate TR initiatives has become a theme of 
academic research (for a review of the discussion see Drolet & Lorenzi, 2011).  
The most popular representations of TR assume a linear model of innovation (Rogers, 
2003), prioritising basic research as the primary source of new discoveries that are 
subsequently developed into therapeutic solutions which are finally diffused to patients 
and the wider society. In the biomedical field, the adoption of this approach sees basic 
scientists at the origin of the innovation process, producing a large amount of 
fundamental knowledge on the molecular or cell level, some of which will be relevant for 
the development of new drugs or therapies. The fundamental knowledge generated by 
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basic scientists moves forward through the stages of a “translational continuum” until it 
is eventually translated into specific benefits for patients or the general population in the 
form of new drugs, devices and new treatment options. Every step in this linear 
progression addresses a specific problem and is undertaken by a specialised group of 
researchers. In this view, the successful application of new knowledge is dependent on 
the successful completion of each and every one of the stages in which the “translational 
continuum is divided (van der Laan & Boenink, 2012). 
Figure 1 A Model of Translational Research Continuum 
 
Indeed, the idea of moving forwards through stages -often coined as “bench to bedside”- 
is well ingrained in most of the existing conceptualizations of TR, both in academia and 
among practitioners (e.g.: Khoury et al., 2007; Sung et al., 2003). This approach to TR is 
not substantially different from the classic linear staged process that characterizes all 
clinical research. What makes TR approaches different is the explicit search for an 
eventual identification of the steps within these processes that become problematic and 
slow down the progression towards application and health benefits. The TR models thus 
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identify a series of translational chasms, gaps or blocks that need to be bridged (Woolf, 
2008). These chasms are viewed as obstacles and are typically described using what has 
come to be known as a “T-terminology” (Dougherty & Conway, 2008): a structured list 
of (T)ranslation gaps to be bridged. According to these models, the main objective of TR 
should be to bridge these gaps so as to facilitate a fast movement of knowledge forward 
along the successive steps from basic research to application. 
One of the first models adopting a T-terminology was developed by the US Institute of 
Medicine’s Clinical Research Roundtable, which identified two main gaps: T1 and T2. 
The first chasm (T1) is related to the transfer of basic discoveries into human clinical 
testing, while T2 refers to the dissemination and adoption of successful clinical 
discoveries into daily clinical practices. As the TR research developed, other scholars 
proposed more detailed models, adding more T-phases to include more chasms to be 
bridged. Westfall et al. (2007) proposed a TR model beginning at T1, where knowledge 
coming from basic science8 moves to human clinical research through the development 
of Phase I and Phase II clinical trials. The T2 chasm comprises the activities related to 
the translation of initial human testing results into clinical practice. Activities such as 
Phase III and Phase IV clinical trials as well as observational studies and survey research 
are considered to occur at this stage. The final gap (T3) deals with the translation into 
practice and dissemination of the new clinical treatment (e.g.: by developing guidelines 
for clinical practice, patients and the general population). More recent models have 
broken down the translational continuum even further by proposing an additional final 
gap (T4) that emerges when trying to advance towards real-world health outcomes by 
                                                 
8 Therefore, the process starts in the “bench” with fundamental discoveries in molecular biology, genetics 
and other basic sciences that may be of interest for understanding human health. 
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promoting the adoption of evidence-based recommendations by health practitioners 
(Khoury et al., 2007).  
Proponents of these linear TR models often recognize that knowledge can also flow from 
the “bedside to the bench.” Marincola (2011), for instance, stresses that hypotheses tested 
in basic research experiments can be based on observational evidence by practitioners. 
Research based on clinical evidence is particularly important because it provides factual 
knowledge collected by practitioners’ observation (e.g.: through direct contact with 
patients) that can be translated into specific hypotheses to be tested in the lab. Yet, 
although the bidirectional nature of TR is frequently acknowledged in most of the TR 
models, the majority of the TR policy initiatives pursue or are implicitly based on a 
unidirectional “bench to bedside” understanding of knowledge generation and 
application, as reflected by the same terminology of consecutive gaps (T1, T2, T3,…) 
that need to be bridged. 
This focus on the identification of T-gaps has posed a series of challenges that have 
framed much research on TR analysis and evaluation and some problems. When looking 
at TR as seeking solutions to tackle different translational gaps, the identification of these 
gaps and the different views of stakeholders on how to address them can lead to different 
understandings of what TR is about (van der Laan & Boenink, 2012) and what specific 
skills translational scientists should develop (Rubio et al., 2010). Littman et al. (2007) 
point out that, for academics, TR represents a channel to test whether novel ideas 
generated on the basic side have the potential to be turned onto practical applications, an 
opportunity to gain observational insights to develop novel scientific hypotheses to be 
tested at the lab, and a means to gain legitimacy and with it obtain improved access to 
research funding. However, for clinical practitioners such as physicians or clinical staff, 
TR is viewed primarily as a response to the need to shorten the path between scientific 
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evidence and actual practice (Davis et al., 2003). Business organizations view TR as a 
process to accelerate the development of a new drug or therapy as well as an opportunity 
to make go/no go decisions at an early stage of the biomedical innovation process –
potentially resulting in major savings by avoiding failed investments. Also, the fact that 
public organisations conduct TR is seen by industry as an opportunity to save 
investments in research where returns are very uncertain. 
Although different communities may hold different views on the objectives of TR, they 
are typically concerned about specific “gaps” among a succession of translational gaps 
that hinder the progression from fundamental knowledge to socially beneficial solutions. 
In doing so, they implicitly or explicitly accept a view that sees knowledge accumulating 
through different stages from fundamental to applied research. Yet, some scholars have 
expressed deep concerns about the adequacy of a linear TR model as a way to frame 
analysis and develop policy strategies (Graham et al., 2006; Littman et al., 2007; 
Marincola, 2011). A linear TR model implicitly builds over a theoretical separation 
between basic and applied research. Although this separation is widely used in the 
practice and analysis of science and technology policy, fundamental knowledge can also 
be sought with a view to solve an applied problem, à la Pasteur. This arguably creates a 
different form of research, “use-inspired basic research” (Stokes, 1997), which fits well 
with the TR goal of generating knowledge with an explicit focus on patient applications 
and public health benefits. However, a TR model based on a linear progression from 
basic science to health applications cannot account for the existence of “user-inspired 
basic research”.  
The idea that knowledge moves forwards and backwards across the unidimensional line 
of the TR continuum partially captures the view of a dynamic relation between basic and 
applied research, but cannot account for the existence of a different type of research 
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where scientists who carry out fundamental research systematically consider potential 
health applications. The TR continuum is understood as a cognitive dimension, but 
empirical observations challenge the very existence of such a continuum. Rather one 
observes a discontinued cognitive line and further dimensions of discontinuation; for 
example, the physical separation between basic and clinical labs, and the different legal 
frameworks and organizational affiliations under which scientists operate.  
“User inspired basic research” is only one example of how the different groups involved 
in the R&D process can interact in complex ways, simultaneously playing different roles, 
and compressing some of the spaces in the different dimensions of discontinuity. For 
instance, some scientists have claimed that the progress of biomedical research 
increasingly depends on a close collaboration between researchers, practitioners, medical 
institutions, patient communities and research sponsors throughout the research lifecycle 
(Meslin, Blasimme, & Cambon-Thomsen, 2013). Collaboration often occurs through 
informal and non-structured channels (Sibbald, Wathen, Kothari, & Day, 2013) and 
hence, it may be particularly challenging to develop and implement policy instruments 
for the governance and evaluation of such interactions. The role of “boundary spanners”, 
actors who facilitate communication across different communities, is particularly 
important here (Lander & Atkinson-Grosjean, 2011; Swan et al., 2007). Boundary 
spanners are individuals who engage in significant transactions with out-group members, 
facilitate knowledge exchange between groups and manage intergroup conflicts (Richter, 
West, Van Dick, & Dawson, 2006). From this perspective, clinical scientists working at 
the interface between basic scientists and health practitioners could play a crucial 
“boundary spanning” role, intermediating between the needs and objectives of the 
different actors, and conveying knowledge across them in a fast and timely manner 
(Kelley et al., 2012). To do so, effective clinical scientists have to develop management 
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and coordination skills and need to be fluent in the different “languages” used by the 
diverse “epistemic cultures” of basic scientists and clinicians (Roberts, Fischhoff, 
Sakowski, & Feldman, 2012). Further, it has been suggested that clinicians working at 
the interface between basic scientists and the final beneficiaries of the research (e.g.: 
patients) may help establish new partnering mechanisms with patients with the objective 
of assessing more effective therapies or performing observational studies (Kelley et al., 
2012). 
All these studies share a concern about the relationship among the diverse groups of 
actors that participate in processes leading to the development of new drugs or therapies. 
For a variety of reasons, which these literatures explore, the links among these 
communities along a variety of dimensions are seen as problematic. Under these 
perspectives the main challenge of TR can be conceptualised differently. Instead of 
focusing on bridging the gaps between successive stages without addressing the 
traditional specialised role of the different actors working in each of the stages, the 
emphasis of TR becomes a redefinition of the interactions among these actors and, 
consequently, a redefinition of their roles. So, for instance, fundamental scientists 
could be involved in TR by conducting “user-inspired research” in close contact with, 
among others, clinicians and patients. Another avenue for TR could be for patient 
organisations to play a role transcending that of a beneficiary, collaborating with 
researchers at all levels in the identification of research problems. Further, clinicians 
could operate as “boundary spanning” actors helping develop these interactions. There 
are many different ways through which a TR approach can establish a much closer 
working interaction among the different actors in the process. Instead of seeing TR as 
addressing the challenges that appear at specific points in a traditional staged linear 
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research system, this approach widens its definition to include the ways in which 
research takes place, and the actors it involves. 
3 Implications	for	TR	evaluation	
The different ways of understanding the notion of TR give way to a variety of policies 
and initiatives with differing objectives and logics which are all branded as translational. 
These different notions are associated with different ways in which TR initiatives and 
policies can be evaluated according to the TR concept that the evaluators, implicitly or 
explicitly, hold. In the preceding section we have defined two main, contrasting, views of 
TR; these views naturally lead to different approaches to the evaluation of TR. We now 
discuss the evaluation approaches that would fit with these views. 
3.1 Gaps	and	lags:	evaluating	the	translational	continuum	
When TR is viewed as an attempt to bridge a series of sequential gaps that hamper the 
translation of research results into socially beneficial applications, evaluation proposals 
focus on the specific gaps that TR is supposed to address rather than the whole research 
and development processes. The success of a program can then be defined by the extent 
to which it has reduced or bridged these gaps. The diversity of evaluation techniques 
proposed emerges because these gaps are defined differently, and the indicators used to 
identify whether a gap has been addressed successfully can also vary. Morris et al have 
reviewed 23 different evaluation papers and concluded that “different studies use 
different measures, of different things, at different time points.” The authors “argue that 
understanding lags first requires agreeing models, definitions and measures, which can be 
applied in practice” (Morris, Wooding, & Grant, 2011). 
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This perspective assumes that the key indicator to assess TR initiatives is the time it takes 
for the different translational gaps to be bridged and, therefore, for research to be 
translated into treatments and other measures improving health. Such time lag is also the 
indicator taken by Trochim and his colleagues (2011) when developing a generic 
evaluation model that could provide the basis for a shared approach to TR evaluation. 
They propose a flexible solution focusing on what they view as the final TR objective: 
the reduction of the time it takes to develop new clinical practices and drugs that reach 
patients. Following a generic linear TR model, they propose to identify “markers” in the 
translation process and assess the time that it takes for outputs to move across markers. 
There is flexibility in the identification of such markers, and therefore there is no need to 
adopt beforehand one model of translational research instead of another. There is also 
flexibility in the direction of the activity across markers, allowing for both “bench to 
bed”, and “bed to bench” directions. Yet, the approach focuses on the outputs of TR and 
on the time it takes for the output of a specific activity to be translated into a different 
type of output identified in another marker. In other words, this form of evaluation is 
concerned by TR outputs rather than the way in which such outputs are achieved.  
Many TR evaluations have followed this route. Even when the programs themselves are 
unclear in the definition of their goals, time lag studies have become an increasingly 
dominant approach. In these studies, the gap between different research phases and the 
outputs they generate ceases to be an indicator of success and is converted into the 
objective of translational research: shortening the time elapsed between different research 
stages becomes what translational research is about. One could argue that there is a risk 
here of the tail of evaluation wagging the dog of translational research: the way in which 
success is measured may define the nature of the research objectives being pursued. 
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Setting aside this problem, focusing on outputs rather than processes has advantages and 
limitations. It can, for instance, draw on traditional indicators, like scientific publications, 
by linking them to a “marker”.9 This can prove convenient as traditional indicators are 
more easily available, but its application is likely to reinforce some of the processes and 
practices that TR is supposed, at least in some of its definitions, to combat. For instance, 
basic scientists can be assessed against their published outputs and in particular the time 
it takes for publication to take place; but the method is unconcerned about the way in 
which such outputs have been generated, how the different research steps are defined and 
the roles of the different actors within these processes. This is problematic if we 
understand TR to be aimed at changing how participants interact. An understanding of 
TR that focuses on the way the research and innovation processes are organized will call 
for different evaluation approaches. Next section outlines an evaluation framework that 
we argue is better suited to address the way in which TR initiatives affect research and 
application processes.TR as an interactive process in multiple dimensions: a proximities 
approach  
The main problem that TR initiatives attempt to address is the difficulty to turn the 
results of basic and applied research into socially beneficial applications. As we have 
seen in the previous sections, a possible indicator to assess whether a TR initiative has 
been successful is to measure the time that research results take to be transformed into 
outputs that bring them closer to final application and social benefits. One potential 
                                                 
9 The notion of translational research has been applied to specific activities designed to cover one of the 
“translational gaps”. For instance, O’Hara and colleagues apply quasi-experimental techniques to the 
evaluation of the implementation and effectiveness of a telephone-delivered information system aimed at 
supporting individuals to make “life-style changes”. This is defined as representing “the translation of 
research evidence applied in the real world (T4 or Phase 4 translation)”, and therefore as providing a 
framework for the evaluation of translational research (O’Hara et al., 2013). From this perspective there is 
nothing peculiar about translational research. An activity to provide information to the public is defined as 
translational and analysed using standard evaluation techniques that are fit for this purpose, but may not be 
adequate to assess the results of other translational activities. 
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problem that this approach can generate, if it spreads as a common approach to TR 
evaluation, is common to all evaluation practices that revolve around a narrow set of 
performance indicators linked to specific outputs: hitting the indicator target may 
inadvertently become the main objective of policies and practices, losing sight of the 
ultimate objective of the investments (in this case, to increase the social benefits of 
research through improved health outcomes). In principle, we do not know how this 
overriding, final goal is to be achieved in each and every specific research context. We 
know, however, that there is a variety of potential ways to achieve it: through the 
development of improved diagnostics, of new drugs, or through primary health 
improvement or prevention in living habits. Each of these different ways involves 
different sets of actors and different socio-technical configurations, and the way these 
actors interact will vary across different organisational and institutional settings. 
Therefore setting up a narrow set of indicators to conduct a “gaps and lags” study is 
appropriate if one is interested in the interaction rather than the outputs.. 
The alternative is to focus on how TR programmes affect the way in which research 
objectives are defined, research is conducted, and its results applied in practice. We can 
assert that TR initiatives attempt to address problems in the organization and 
management of biomedical research by bridging the divide between different actors 
involved in the development of new drugs, therapies, diagnostics or public health 
practices. The different groups include, for instance, doctors and patients involved in the 
identification and definition of therapeutic and health problems, researchers defining and 
addressing relevant fundamental research challenges, and clinicians and doctors 
developing and testing solutions. The separation among these actors takes various forms: 
the different groups belong to different organizations, follow different implicit and 
explicit rules, and respond to different sets of incentives and performance criteria. These 
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conflicting logics (Sauermann & Stephan, 2013) and epistemic cultures (Knorr-Cetina, 
1999) can make it difficult to align the objectives among the parties, and to establish 
clear and fluid lines of communication. This type of separation results in a difficulty to 
communicate needs and results across communities separated by institutional and 
organisational boundaries.  
TR initiatives can then seek to reduce some of the divides among biomedical innovation 
actors. TR would then take place in networks of diverse actors, such a basic research, 
clinical doctors, general practitioners, regulators, etcetera. It is important to emphasise 
the networked nature of the social interactions: basic research, for instance, can be 
influenced by insights from general practitioners and from regulators, without the 
mediation of clinical doctors.  
We propose that these interactions are less than optimal because the distances that 
separate these different groups make the interactions difficult. Following Boschma 
(2005), we can state that learning processes and knowledge exchange interactions are 
facilitated and strengthened by five forms of proximity: cognitive, social, 
organisational, institutional and spatial.  
A degree of cognitive proximity - i.e. the extent to which actors share a similar 
knowledge base - is a prerequisite for interactive learning, as it facilitates effective 
communication and a common reference space to process and transfer complex 
information and knowledge. However, as pointed out by Nooteboom (2000) and 
Boschma (2005), both too much and too little cognitive proximity can be detrimental to 
innovation and learning processes. A high degree of cognitive proximity between actors 
may lead to the exchange of irrelevant, redundant information due to a lack of variety of 
the knowledge sources; while too little cognitive diversity may lead to information 
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exchange that cannot be adequately understood by the interacting actors, rendering 
communication ineffective.  
Social proximity refers to relations between actors generally built on common 
experience, friendship and kinship and which can improve communication. 
Organisational proximity refers to the governance structure shaping interactions between 
actors. High organisational proximity is often associated with a hierarchical structure 
governing the interactions between actors, while low organisational proximity is 
generally associated with flat governance structures or arms’ length interactions between 
actors. Institutional proximity refers to the norms, rules and values that influence how 
actors behave; a large institutional distance may impose serious impediments to fruitful 
learning interactions if the behaviour of interacting actors responds to different, 
potentially conflicting, sets of incentives or values. For example, universities and firms 
have considerable institutional distance because their incentives and norms differ 
significantly. Finally, geographical proximity refers to the spatial or physical distance 
between actors. This matters in knowledge dynamics because spatial co-location favours 
the exchange of knowledge that is complex or difficult to transfer (i.e. tacit knowledge). 
All these types of proximity are inter-related. Some may complement each other, while 
others may act as substitutes. For instance, Harrison (1992) and Howells (2002) argue 
that geographical proximity facilitates face-to-face interactions, favouring trust-based 
relationships and knowledge exchange, suggesting a reinforcing effect of spatial 
proximity on social proximity. In contrast, some proximity dimensions may substitute 
each other: barriers for knowledge exchange through large geographical distances 
(spatial distance) might be overcome if interacting partners share a well-defined and 
honed division of labour (i.e. organisational proximity) (Rallet & Torre, 1999). 
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Coming back to TR initiatives, these can explicitly or implicitly address perceived 
distance problems along one or more of these analytical dimensions. They can for 
instance establish ways to improve communication and understanding between patients, 
clinicians and researchers (addressing cognitive distance), they may try to establish better 
coordination across different organisations involved in the research and application 
process (addressing organisational distance), align their incentives rules and norms 
(addressing institutional distance), or improve trust (addressing social distance). In other 
words, TR initiatives can be described as aiming to bridge the gaps among the actors 
involved in biomedical research and the application of its results by directly reducing the 
distance among the actors in one or more of the five analytical dimensions.  
4 TR	Evaluation:	Increasing	proximities	and	“programme	
theories”	
We argue that we can interpret policy initiatives fostering TR as aiming to have an 
impact in one or various proximity dimensions. In this way we can interpret their 
“programme theory” (their goals and the processes through which these goals are to be 
achieved) as revolving around the attempt to develop proximities. This would be the first 
step in a TR evaluation strategy that could be presented as an alternative to the dominant 
“gaps and lags” approach. Different TR policies and initiatives have different goals and 
targets. The section below shows how the dimensions of proximity proposed by 
Boschma can be used to describe the “programme theory” of TR initiatives drawing on 
two contrasting examples: the centre IDIBAPS and the CIBER networks initiative. 
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4.1 Collaborative	 Centres	 pursuing	 spatial	 proximity:	 the	 case	 of	
IDIBAPS	
IDIBAPS is a translational research centre located right across the street from the Clinic 
Hospital of Barcelona. It houses some 460 researchers with diverse institutional 
affiliations: the hospital itself, the University of Barcelona, Spanish and Catalan research 
establishments (CSIC and ICREA), and its own staff. It is thus organized as a space 
providing common facilities where researchers with different affiliations and expertise 
work together. IDIBAPS can be described as a TR initiative aiming primarily to increase 
spatial proximity. Spatial proximity is necessary to allow shared access to research 
facilities thus increasing efficiency. IDIBAPS researchers have access to bioinformatics 
and medical imaging facilities as well as the hospital biobank. In addition, and equally 
important, spatial proximity is expected to generate other forms of proximity; for 
instance, IDIBAPS working practices are expected to a spirit of trust and collaboration 
among different actors (thus increasing social proximity). Further IDIBAPS researchers 
work within the rules and incentive systems of the Institute (often overlapping with those 
of their parent organisations); the objective here is to align such incentive systems and 
norms and thus generate institutional proximity. Ultimately, these proximities should 
facilitate knowledge flows (increasing cognitive proximity) among different epistemic 
cultures. An evaluation of an organisation like IDIBAPS should therefore seek to 
determine whether and how these expectations take place.  
4.2 Collaboration	 networks	 seeking	 organisational	 proximity:	 the	
CIBERs	
The Biomedical Research Networking Centres (henceforth, CIBERs) were established in 
2006 by the Spanish Government to promote excellence in biomedical research through 
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the establishment of stable structures of cooperative research. The CIBERs were selected 
through an open call to biomedical research groups. Applicants had to establish a broad 
network of research groups, which could be placed at Universities, Public Research 
Organizations, Hospitals, Clinics and research foundations. Nine CIBER research 
networks were founded between 2006 and 2007, each focused on a specific pathology or 
disease of strategic interest to the Spanish National Health System10 and were expected to 
carry out TR. Each CIBER “platform” is an independent legal entity formed by the 
association of various research groups geographically dispersed.  
Members of the CIBERs continue to work in their own organizations and, therefore, we 
can state that increasing spatial proximity is not an objective of the initiative. While, the 
diverse biomedical groups within a CIBER remain part of different institutional and 
organizational contexts such as universities, hospitals or public research entities, the 
objective is to coordinate their work, connecting them through the common legal and 
economic framework provided by the CIBER platform. As far as the work to be 
conducted under the initiative is concerned, the CIBER platform provides a hierarchical 
governance structure to catalyze coordinated action among the actors involved in the TR 
process. By connecting these research groups through hierarchical mechanisms and 
common practices and decision making processes, the CIBER platform aims to increase 
organizational proximity among a group of heterogeneous research actors.  
Furthermore, although the groups belonging to a CIBER are only “loosely coupled”11 we 
can expect that, by setting some basic conditions for the creation of common rules and 
                                                 
10 Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Epidemiology and Public Health 
(CIBER-ESP), Obesity and Nutrition (CIBER-OBN), Hepatic and Digestive Diseases (CIBER-EHD), 
Neurodegenerative Diseases (CIBER-NED), Respiratory Diseases (CIBER-ES), Rare Diseases (CIBER-
ER), Mental Health (CIBER-SAM) and Diabetes and Metabolic Associated Diseases (CIBER-DEM). 
11 Loosely coupled networks are organisational structures that may help coordinate transactions among 
highly heterogeneous partners, providing a balance between mechanisms of control and flexibility. Loosely 
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shared expectations, the CIBERs may provide the means to generate social proximity, 
and through it increase cognitive proximity. In other words, we understand the network 
as an organisational arrangement, which aims, primarily, to increase organisational 
proximity among all actors (basic researchers, doctors, patient groups), who tend to be 
distant in all dimensions. This organisational proximity improves, in turn, the proximities 
in the social sphere which may facilitate flows in the cognitive dimension. 
5 Analysing	 proximities	 and	 their	 effects:	 the	 need	 for	
diverse	techniques	and	the	difficulties	of	comparability	
The focus on processes that underpins the evaluation approach we suggest here is based 
on the postulate that to understand the effect of TR initiatives we need to learn about how 
they affect the ways in which research, its objectives and the application of its results are 
designed and conducted. An evaluation strategy that focuses only on measuring outputs 
cannot offer information on how the initiative under evaluation has contributed to the 
observed outputs. When, as it is the case with TR, there is ambiguity about what 
differentiates this from of research from other forms of research, the need to understand 
how interventions operate in practice and what processes they trigger is particularly 
important. We have explored in this paper an avenue to develop a process-based 
approach to the evaluation of TR initiatives.  
Evaluation frameworks are not neutral in relation to the objectives of an initiative. The 
way in which a project is evaluated will affect how it is conducted and, at least, part of 
the objectives that the performers will be aiming at. Focusing on specific outputs can 
implicitly suggest an intervention rationale that is not concerned about the organisation 
                                                                                                                                                 
coupled networks are somewhere in between highly hierarchical organisational structures that may impose 
too strong a degree of control and bureaucracy for learning-related activities, and weakly articulated 
governance structures that provide a fragile setting for building trust-based and sustainable relationships.  
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of research, and the way in which specific “translational gaps” are addressed. The 
proximities framework we are proposing can help focus attention on the way research is 
conducted and the specific aspects that an initiative is intended to address. These aspects 
may be explicit in the definition of the intervention, but they can also be implicit in the 
way the initiative is implemented. In the latter case, the framework can also be used to 
explore and develop a “programme theory” for a TR; that is to explore its rationale. The 
cases above show how we can use the framework to describe both the goals of TR 
initiatives and the way such goals are expected to be attained.  
By adopting this approach we are proposing that the immediate goal of TR initiatives is 
to address a problem of distance separating different groups involved in the TR process. 
The “translational gaps” appear because of excessive distance in one or more significant 
dimensions. The groups involve in the translational process have cognitive differences, 
are institutionally separated and, therefore, follow different rules, face different types of 
incentives, and they are often geographically dispersed. Yet, some flexibility must be 
built into the definition of an initiative and its evaluation to reflect the fact that increased 
proximity will not always be desirable. For instance, cognitive distance can pose a 
problem but the same can be said of the overlaps generated by excessive cognitive 
overlap; cognitive proximity will be positive only up to a certain extent. A specific 
programme theory will need to reflect this problem and the interpretation of evaluation 
results will have to be sensitive to this potential problem if there is a possibility that it 
may become relevant. 
The programme theory of a TR initiative will define the expectations about whether and 
how changes in proximity in one or more dimensions caused by the intervention will 
trigger shifts in the other dimensions, and the effects of these changes on the 
development and application of beneficial goods and services. These effects will be 
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mediated by changes in the way in which research is carried out. Increased proximity can 
result in increased collaboration among groups involved in the different tasks that 
constitute the TR process (the definition of fundamental and clinical research objectives, 
research, and the application of its results). We can expect changes in proximity to 
generate new interactions across groups, like for instance, between research performers 
and the diverse users and beneficiaries of the research results, where knowledge is 
moving back and forth through various channels, not in the linear bedside to bench 
continuum but within networks.  
We can thus define further building blocks of a TR programme theory. An intermediate 
outcome of increased proximities can be the generation of complex interactions among 
different groups that become partners in a single TR process. An analysis of intermediate 
outcomes in terms of interactions among the participants in the TR process needs to 
consider the variety of actors directly involved and affected by a TR initiative. Although 
this may vary across initiatives, it is important to take into account that there is a broad 
variety of potential stakeholders: basic researchers, clinical researchers, technologists, 
practitioners (doctors, nurses,…), public health and private industry managers, patients. 
The ways in which stakeholder groups interact can be traced and analysed using 
instruments developed for the evaluation of the socio-economic impact of research, like 
for instance those developed by the EU-funded SIAMPI project (Molas-Gallart & Tang, 
2011; Spaapen & van Drooge, 2011), which focus on the processes of collaboration that 
can be linked to an initiative.  
Our framework does not determine the research techniques to be employed; these will 
need to fit the specific circumstances of each initiative under assessment. The activities 
supported by a TR initiative will be different, implemented against different contexts and 
having different targets and objectives. For instance, the research techniques applied to 
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an initiative that focuses mainly on cognitive issues, will be different from those applied 
to one that addresses institutional differences. 
Finally, as the adequacy of a specific research technique will depend on the specific TR 
evaluation problem confronted and its context, it follows that the outputs of TR 
evaluations will not, and should not, be directly comparable. Calls for an approach that 
will be based on a single set of research techniques yielding measurable and comparable 
indicators of TR “output” are, from the perspective we are developing, out of place. An 
evaluation approach that focuses on processes will aim at providing detailed information 
of the effects of an initiative starting at the level of those groups directly involved in it. 
But the way in which this information is shaped, and the indicators on which it is based 
will depend on the type of initiative, its objectives and the types of proximities the 
programme is designed to address. 
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